Semaglutide's UK Approval for Obesity Management — a Plain-English Guide

Step 1: The original MHRA licence and what it covered

Wegovy's MHRA approval for weight management came before NICE had appraised it for NHS use. The licence set the core eligibility: adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. Treatment is taken alongside a reduced-calorie diet and increased physical activity, the licence does not frame this as a standalone fix.

The dosing structure approved at that point started at 0.25mg weekly and escalated in roughly four-weekly steps through 0.5mg, 1mg, and 1.7mg to a 2.4mg maintenance dose. Each step is managed by the prescriber, not self-selected. Our overview of semaglutide covers the mechanism and the clinical evidence in more detail if you want the fuller picture before reading on.

A Black Triangle (▼) designation was applied, meaning the MHRA collects additional data on safety in routine use. That designation is common with newly licensed medicines and does not indicate a problem, it is a monitoring signal. If you are curious about how semaglutide reached this point, our page on the semaglutide first approval explains the original regulatory journey that led to it being licensed. Patients and clinicians can report any suspected side effects through the MHRA Yellow Card scheme, which remains the right channel for any concerns during treatment.

Step 2: NICE's recommendation and the NHS eligibility criteria that followed

NICE appraised semaglutide separately and published guidance (TA875) recommending it for NHS use, but with conditions that are considerably tighter than the product licence alone. Under TA875, NHS semaglutide treatment requires use within a specialist weight management service offering multidisciplinary support, at least one weight-related comorbidity, a BMI of 35 or above (or 30 to 34.9 in specific circumstances), and a maximum treatment duration of two years. Lower BMI thresholds (typically 2.5 kg/m² less) apply for South Asian, Chinese, Middle Eastern, Black African, and African-Caribbean backgrounds under UK guidance.

NICE also set a review trigger: if someone has not lost at least 5% of their body weight after six months on the maintenance dose, continuing treatment should be reconsidered. The NICE technology appraisal TA875 sets out all of these criteria in detail and is the document NHS commissioners work from. NHS waiting lists for specialist services are often long, which is one reason many people look at the private prescription route instead.

For context on how the approval timeline fits together, our page on the semaglutide approval date gives a chronological breakdown. The Wegovy UK approval page goes deeper on the regulatory sequence if you need it for a specific reference.

Step 3: The 7.2mg approval and what changed in 2026

On 14 April 2026 the MHRA approved a dedicated single-dose 7.2mg semaglutide pen, designed so each weekly injection is pre-set, the needle is covered automatically, and the pen locks after use. This followed an earlier approval of the 7.2mg dose itself (delivered initially as three 2.4mg pens per week), and it represents the current maximum maintenance dose in the Wegovy schedule. Clinical data reported average weight loss of around 20.7% over 72 weeks at 7.2mg, narrowing the gap with tirzepatide 15mg results from the SURMOUNT programme.

The 7.2mg approval applies to adults with obesity (BMI 30 or above) and is not approved for the cardiovascular indication or for BMI below 30. The starting dose remains 0.25mg, escalating under prescriber supervision; 7.2mg is not a starting point. You can read the MHRA's announcement on GOV.UK's news page for the 7.2mg pen approval.

Separately, semaglutide received conditional UK approval in July 2026 for metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease. That is a distinct indication; our semaglutide MASH approval page covers what that means in practice. The two approvals are independent, having MASH does not automatically qualify someone for the obesity licence, and vice versa.

What the approvals mean if you are considering treatment now

The short practical answer is that semaglutide for obesity is available in the UK through two routes: via the NHS under TA875's specialist-service criteria (with the caveats on waiting times and the two-year cap), or through a private prescription following an individual clinical assessment. Both routes require a prescriber to review your health history, current medicines, and BMI before issuing a prescription, there is no shortcut around that step.

One thing worth doing before any consultation takes about 30 seconds: check that any pharmacy you are considering is on the GPhC register at pharmacyregulation.org/registers. A registered premises number should be visible on the pharmacy's own website. At nume, our GPhC premises registration number is 9012878, verifiable directly on that register. It is a small check that filters out a lot of risk quickly.

If you want to understand the full range of weight-loss options available, our weight-loss treatment overview sets out what is licensed, how each approach works, and who each one suits. For those specifically interested in Wegovy, our Wegovy information page covers the clinical evidence, side-effect profile, and what to expect during treatment. When you are ready to discuss whether treatment is right for you, you can start your free consultation with our prescribing team, a qualified GPhC-registered Independent Prescriber reviews every submission the same day.